GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
GILEAD SCIENCES, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $29.82B | $29.25B | $28.92B | $28.55B | $28.72B | $28.58B | $28.61B | $28.14B | $27.62B | $27.28B | $26.93B | $27.20B | 97.9% | +3.8% |
| Total HIV | $21.80B | $21.20B | $20.75B | $20.40B | $20.20B | $19.86B | $19.61B | $18.85B | $18.45B | $18.33B | $18.18B | $18.26B | 71.6% | +7.9% |
| Biktarvy | $14.79B | $14.55B | $14.33B | $14.14B | $13.93B | $13.63B | $13.42B | $12.76B | $12.37B | $12.12B | $11.85B | $11.66B | 48.6% | +6.2% |
| Total Oncology | $3.31B | $3.29B | $3.24B | $3.24B | $3.27B | $3.26B | $3.29B | $3.21B | $3.16B | $3.05B | $2.93B | $2.78B | 10.9% | +1.4% |
| Total Liver Disease | $3.31B | $3.23B | $3.22B | $3.09B | $3.01B | $3.04B | $3.02B | $2.99B | $2.97B | $2.85B | $2.78B | $2.79B | 10.9% | +10.1% |
| Descovy | $3.29B | $2.98B | $2.76B | $2.56B | $2.44B | $2.27B | $2.11B | $2.01B | $1.93B | $1.96B | $1.99B | $2.01B | 10.8% | +34.9% |
| Total Cell Therapy | $1.71B | $1.78B | $1.84B | $1.87B | $1.92B | $1.96B | $1.97B | $1.95B | $1.95B | $1.90B | $1.87B | $1.82B | 5.6% | -10.8% |
| Trodelvy | $1.60B | $1.51B | $1.40B | $1.37B | $1.34B | $1.30B | $1.32B | $1.26B | $1.21B | $1.15B | $1.06B | $960.00M | 5.3% | +19.0% |
| Yescarta | $1.40B | $1.44B | $1.50B | $1.52B | $1.56B | $1.58B | $1.57B | – | – | – | – | – | 4.6% | -10.3% |
| Genvoya | $1.31B | $1.40B | $1.50B | $1.59B | $1.66B | $1.72B | $1.76B | $1.81B | $1.86B | $1.96B | $2.06B | $2.18B | 4.3% | -21.1% |
| Sofosbuvir/Velpatasvir | $1.17B | $1.21B | $1.27B | $1.33B | $1.40B | $1.54B | $1.60B | $1.64B | $1.64B | $1.56B | $1.54B | – | 3.8% | -16.5% |
| Vemlidy | $1.09B | $1.06B | $1.07B | $1.04B | $996.00M | $987.00M | $959.00M | $917.00M | $913.00M | $889.00M | $862.00M | – | 3.6% | +9.7% |
| Odefsey | $1.05B | $1.11B | $1.17B | $1.19B | $1.24B | $1.26B | $1.29B | $1.29B | $1.31B | $1.34B | $1.35B | $1.40B | 3.4% | -15.6% |
| Total Other | $746.00M | $787.00M | $799.00M | $779.00M | $796.00M | $874.00M | $889.00M | $906.00M | $921.00M | $884.00M | $859.00M | $911.00M | 2.4% | -6.3% |
| Other Liver Disease | $744.00M | $749.00M | $874.00M | $605.00M | $490.00M | $480.00M | $467.00M | $432.00M | $418.00M | $400.00M | $385.00M | – | 2.4% | +51.8% |
| Veklury | $655.00M | $753.00M | $911.00M | $1.04B | $1.45B | $1.55B | $1.80B | $2.18B | $2.12B | $2.17B | $2.18B | $2.47B | 2.2% | -54.9% |
| Royalty, contract and other revenues | $636.00M | $487.00M | $527.00M | $538.00M | $144.00M | $158.00M | $144.00M | $154.00M | $180.00M | $174.00M | $182.00M | $194.00M | 2.1% | +341.7% |
| Symtuza - Revenue share | $533.00M | $519.00M | $495.00M | $506.00M | $521.00M | $565.00M | $592.00M | – | – | – | – | – | 1.8% | +2.3% |
| AmBisome | $489.00M | $508.00M | $509.00M | $500.00M | $507.00M | $529.00M | $533.00M | $536.00M | $521.00M | $521.00M | $492.00M | $499.00M | 1.6% | -3.6% |
| Other HIV | $431.00M | $467.00M | $500.00M | $407.00M | $395.00M | $408.00M | $434.00M | $402.00M | $396.00M | $411.00M | $401.00M | – | 1.4% | +9.1% |
| Tecartus | $318.00M | $340.00M | $344.00M | $351.00M | $366.00M | $381.00M | $403.00M | $403.00M | $401.00M | $382.00M | $370.00M | $355.00M | 1.0% | -13.1% |
| Other | $256.00M | $278.00M | $290.00M | $279.00M | $289.00M | $346.00M | $356.00M | $371.00M | $401.00M | $363.00M | $367.00M | $547.00M | 0.8% | -11.4% |
| Letairis | – | – | – | – | – | – | – | – | – | – | $142.00M | $168.00M | – | – |
| Other HIV | – | – | – | – | – | – | – | – | – | – | $56.00M | $54.00M | – | – |
| Revenue share - Symtuza | – | – | – | – | – | – | – | – | – | – | $529.00M | $531.00M | – | – |
| Complera/Eviplera | – | – | – | – | – | – | – | – | – | – | $129.00M | $163.00M | – | – |
| Stribild | – | – | – | – | – | – | – | – | – | – | $101.00M | $108.00M | – | – |
| Truvada | – | – | – | – | – | – | – | – | – | – | $114.00M | $141.00M | – | – |
| Ledipasvir/Sofosbuvir | – | – | – | – | – | – | – | – | – | – | $70.00M | $85.00M | – | – |
| Sofosbuvir/Velpatasvir | – | – | – | – | – | – | – | – | – | – | $1.54B | $1.53B | – | – |
| Total HCV | – | – | – | – | – | – | – | – | – | – | $1.77B | $1.77B | – | – |
| Vemlidy | – | – | – | – | – | – | – | – | – | – | $862.00M | $866.00M | – | – |
| Other HB/HDV | – | – | – | – | – | – | – | – | – | – | $72.00M | $64.00M | – | – |
| Total HBV/HDV | – | – | – | – | – | – | – | – | – | – | $1.02B | $1.01B | – | – |
| Viread | – | – | – | – | – | – | – | – | – | – | $83.00M | $83.00M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $21.69B | $21.13B | $20.88B | $20.57B | $20.74B | $20.63B | $20.59B | $20.21B | $19.78B | $19.62B | $19.44B | $19.52B | 71.2% | +4.6% |
| Europe | $5.26B | $5.12B | $5.06B | $5.00B | $4.62B | $4.56B | $4.63B | $4.62B | $4.50B | $4.39B | $4.31B | $4.24B | 17.3% | +14.0% |
| Rest of World | $3.51B | $3.48B | $3.50B | $3.52B | $3.51B | $3.55B | $3.53B | $3.47B | $3.53B | $3.44B | $3.37B | – | 11.5% | -0.0% |
| Rest of World | – | – | – | – | – | – | – | – | – | $3.44B | $3.37B | $3.64B | – | – |
From the segment and revenue-disaggregation notes of Gilead Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.